About orbsen

This author has not yet filled in any details.
So far orbsen has created 18 blog entries.
31 01, 2023

Orbsen Therapeutics announces encouraging interim results from the NEPHSTROM proof of concept clinical study evaluating ORBCEL™ cell therapy in patients with diabetes and advanced chronic kidney disease

2023-01-31T23:16:28+00:00January 31st, 2023|

GALWAY, Ireland, Jan. 26, 2023 /PRNewswire/ -- Orbsen Therapeutics Limited ("Orbsen"), a global leader in stromal cell immunotherapies, today announces encouraging headline interim results from the EU Horizon 2020-funded NEPHSTROM clinical trial for Diabetic Kidney Disease (NEPHSTROM). NEPHSTROM is a randomized, double-blind, placebo-controlled Phase 1/2a, trial evaluating the safety, tolerability and preliminary efficacy of an off-the-shelf allogeneic bone [...]

9 02, 2021

Orbsen in fundraising efforts to drive Phase II and potentially Phase IIb mesenchymal stromal cell therapy plans; Phase IIb start likely in mid to late 2021, exec says

2023-01-31T21:24:45+00:00February 9th, 2021|

Orbsen in fundraising efforts to drive Phase II and potentially Phase IIb mesenchymal stromal cell therapy plans; Phase IIb start likely in mid to late 2021, exec says Published Date:20 Apr 2020   Phase IIb could include COVID-19 focus depending on results Orbsen in talks with and open to CMOs to manage downstream manufacturing   [...]

8 04, 2020

Orbsen Therapeutics Launches Clinical Trial to Address Leading Cause of Death Among COVID-19 Patients

2020-04-10T17:40:14+00:00April 8th, 2020|

GALWAY, Ireland, April 8, 2020 /PRNewswire/ -- Orbsen Therapeutics, a biotechnology company focused on the development and commercialization of best-in-class stromal cell immunotherapies, announced the beginning of a phase 2a clinical trial for the treatment of COVID-19 patients with acute respiratory distress syndrome (ARDS). Nearly 90 percent of deaths caused by COVID-19 are the result of ARDS.

1 07, 2019

Minister opens new Business Innovation Centre for life sciences start-ups

2019-07-01T18:03:10+00:00July 1st, 2019|

The new development complements the University’s existing Business Innovation Centres which are home to 52 early-stage companies. The University’s focus with the new Business Innovation Centre – North at Dangan Business Park is in driving Life Sciences research and innovation to develop services and solutions that demonstrably improve outcomes for patients through solutions that save [...]

9 04, 2019

Clinical Trial Investigates Orbsen Therapeutics’ ORBCEL-C™ Immunotherapy as Treatment for two Autoimmune Liver Diseases

2019-04-09T20:54:20+00:00April 9th, 2019|

Orbsen Therapeutics, a biotechnology company focused on the development and commercialization of first-in-class stromal cell immunotherapies, announced its second generation immunotherapy ORBCEL-C™ is being administered to patients participating in MERLIN, a multi-site United Kingdom-based clinical trial to determine the therapy’s safety and effectiveness in treating two types of chronic autoimmune liver diseases. “Orbsen’s product [...]

2 04, 2019

Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland

2019-04-03T21:28:42+00:00April 2nd, 2019|

Orbsen Therapeutics Moves Into New Headquarters in Galway, Ireland Progress in company’s product pipeline requires move to larger facilities (2 April 2019) Galway, Ireland — Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced it will move its base of operations from the National University [...]

2 10, 2018

Orbsen Therapeutics’ NEPHSTROM Clinical Trial Underway at Four European Union Locations

2019-04-09T20:49:47+00:00October 2nd, 2018|

Orbsen Therapeutics’ NEPHSTROM Clinical Trial Underway at Four European Union Locations Patients with diabetic kidney disease are being treated with a breakthrough stromal cell immunotherapy (October 2, 2018) Galway, Ireland — Orbsen Therapeutics, a biotechnology company focused on the discovery, development and commercialization of first-in-class stromal cell immunotherapies, announced that ORBCEL-M™, a second generation [...]

22 02, 2018

Irish Times Features

2018-03-06T20:17:18+00:00February 22nd, 2018|

NUI Galway leads stem-cell research on diabetic kidney disease, €1.7m in funding for twenty new high-potential research projects announced, Scientific research projects get €1.7million funding boost, Orbsen Therapeutics to take part in €6m liver disease clinical trial, Innovation Awards profile: Orbsen Therapeutics – Stem cell research, The cream of start-ups, college spin-offs and smooth operators. […]

22 02, 2018

Dr. Larry Couture Named CEO Of Orbsen Therapeutics

2018-03-15T12:35:48+00:00February 22nd, 2018|

NEW YORK, Sept. 6, 2016 /PRNewswire/ — Dr. Jack Kavanaugh, Chairman of Orbsen Therapeutics (http://www.orbsentherapeutics.com/), announced today the appointment of Larry Couture, PhD, as CEO. “Dr. Couture brings a remarkable background in cellular and genetic therapeutics with industry leading experience in both the scientific and business development of leading edge therapeutics,” said Kavanaugh. He added, “His industry experience at [...]

Go to Top